SEARCH

SEARCH BY CITATION

References

  • 1
    Nambi V, Hoogwerf BJ, Sprecher DL. A truly deadly quartet: Obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. Cleve Clin J Med2002;69:985989.
  • 2
    Friedman JE, Ishizuka T, Liu S, Farrell CJ, Koletsky RJ, Bedol D, Ernsberger P. Anti-hyperglycemic activity of moxonidine: Metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press1998;3:3239.
  • 3
    De Luca N, Izzo R, Fontana D, Iovino G, Argenziano L, Vecchione C, Trimarco B. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens2000;18:15151522.
  • 4
    Hansson L. Therapy of hypertension and metabolic syndrome: Today's standard and tomorrow's perspectives. Blood Press1998;3:2022.
  • 5
    Srivastava BK, Insulin MV. A Vasoactive Hormone. Int J Diab Dev Ctries2002;22:111114.
  • 6
    Egan BM. Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep2003;5:247254.
  • 7
    Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. Rev Cardiovasc Med2003;4(Suppl 6):S50S57.
  • 8
    Hausberg M, Hoffman RP, Somers VK, Sinkey CA, Mark AL, Anderson EA. Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension1997;29:700705.
  • 9
    Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest2000;106:453458.
  • 10
    Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation1997;96:41044113.
  • 11
    Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med2000;342:905912.
  • 12
    Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension2006;48:219224.
  • 13
    Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ1989;298:11521157.
  • 14
    Swislocki AL, Hoffman BB, Sheu WH, Chen YD, Reaven GM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med1989;86(1B): 1418.
  • 15
    Andersson PE, Johansson J, Berne C, Lithell H. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens1994;8:219226.
  • 16
    Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities–the role of insulin resistance and the sympathoadrenal system. N Engl J Med1996;334:374381.
  • 17
    Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension2002;40:329334.
  • 18
    Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Hirohashi K. Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents2005;3:6167.
  • 19
    Dollery CT, Davies DS, Draffan GH, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther1976;19:1117.
  • 20
    Davies DS, Wing AM, Reid JL, Neill DM, Tippett P, Dollery CT. Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. Clin Pharmacol Ther1977;21:593601.
  • 21
    Wing LM, Reid JL, Davies DS, Neill EA, Tippett P, Dollery CT. Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol1977;12:463469.
  • 22
    Head GA, Burke SL. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit. J Hypertens1998;16:503517.
  • 23
    De Sarro GB, Ascioti C, Froio F, Libri V, Nistico G. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol1987;90:675685.
  • 24
    Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology1992;76:948952.
  • 25
    Correa-Sales C, Reid K, Maze M. Pertussis toxin-mediated ribosylation of G proteins blocks the hypnotic response to an alpha 2-agonist in the locus coeruleus of the rat. Pharmacol Biochem Behav1992;43:723727.
  • 26
    Nicholas AP, Pieribone V, Hokfelt T. Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: An in situ hybridization study. J Comp Neurol1993;328:575594.
  • 27
    Nicholas AP, Hokfelt T, Pieribone VA. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol Sci1996;17:245255.
  • 28
    Sun MK, Reis DJ. GABA-mediated inhibition of pacemaker neurons of rostral ventrolateral medulla by clonidine in vitro. Eur J Pharmacol1995;276:291296.
  • 29
    Scholtysik G, Lauener H, Eichenberger E, Burki H, Salzmann R, Muller-Schweinitzer E, Waite R. Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100–141). Arzneimittelforschung1975;25:14831491.
  • 30
    Ernsberger P, Giuliano R, Willette RN, Reis DJ. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther1990;253:408418.
  • 31
    Ernsberger P, Giuliano R, Willette RN, Granata AR, Reis DJ. Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2-adrenergic receptors in the rostral ventrolateral medulla. J Hypertens Suppl1988;6:S554S557.
  • 32
    Meeley MP, Ernsberger P, McCauley PM, Reis DJ. Clonidine-specific antibodies as models for imidazole and alpha 2-adrenergic receptor binding sites: Implications for the structure of clonidine-displacing substance. J Hypertens Suppl1988;6:S490S493.
  • 33
    Head GA. Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents. Ann N Y Acad Sci1999;881:279286.
  • 34
    Trenk D, Wagner F, Jahnchen E, Planitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol1987;27:988993.
  • 35
    Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl1999;17:S29S35.
  • 36
    Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract Suppl2004;139:2632.
  • 37
    Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, Godicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes2004;112:315322.
  • 38
    Bock C, Niederhoffer N, Szabo B. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine. Naunyn Schmiedebergs Arch Pharmacol1999;359:262271.
  • 39
    Hieble JP, Kolpak DC. Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors. Br J Pharmacol1993;110:16351639.
  • 40
    Vayssettes-Courchay C, Bouysset F, Cordi AA, Laubie M, Verbeuren TJ. A comparative study of the reversal by different alpha 2-adrenoceptor antagonists of the central sympatho-inhibitory effect of clonidine. Br J Pharmacol1996;117:587593.
  • 41
    Urban R, Szabo B, Starke K. Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptorsJ Pharmacol Exp Ther1994;270:572578.
  • 42
    Urban R, Szabo B, Starke K. Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur J Pharmacol1995;282:1928.
  • 43
    Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J Pharmacol Exp Ther1984;230:232236.
  • 44
    Bousquet P. Imidazoline receptors: From basic concepts to recent developments. J Cardiovasc Pharmacol1995;26(Suppl 2):S1S6.
  • 45
    Raddatz R, Parini A, Lanier SM. Localization of the imidazoline binding domain on monoamine oxidase B. Mol Pharmacol1997;52:549553.
  • 46
    Brown CA, Chan SL, Stillings MR, Smith SA, Morgan NG. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080. Br J Pharmacol1993;110:10171022.
  • 47
    Ferry D, Armah BI, Goll A, Glossmann H. Characteristics of the binding of the antihypertensive agent moxonidine to alpha 2-adrenoceptors in rat brain membranes. Arzneimittelforschung1988;38:14421445.
  • 48
    Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P. The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur J Pharmacol1989;162:19.
  • 49
    Kamisaki Y, Ishikawa T, Takao Y, Omodani H, Kuno N, Itoh T. Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: Distribution of imidazoline binding sites in rat brain. Brain Res1990;514:1521.
  • 50
    Ernsberger P, Meeley MP, Mann JJ, Reis DJ. Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol1987;134:113.
  • 51
    Garcia-Sevilla JA, Escriba PV, Guimon J. Imidazoline receptors and human brain disorders. Ann N Y Acad Sci1999;881:392409.
  • 52
    Piletz JE, Jones JC, Zhu H, Bishara O, Ernsberger P. Imidazoline receptor antisera-selected cDNA clone and mRNA distribution. Ann N Y Acad Sci1999;881:17.
  • 53
    Ivanov TR, Jones JC, Dontenwill M, Bousquet P, Piletz JE. Characterization of a partial cDNA clone detected by imidazoline receptor-selective antisera. J Auton Nerv Syst1998;72:98110.
  • 54
    Ruggiero DA, Regunathan S, Wang H, Milner TA, Reis DJ. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res1998;780:270293.
  • 55
    Piletz JE, Andrew M, Zhu H, Feng YZ, Rains J, Halaris A. Alpha 2-adrenoceptors and I1-imidazoline binding sites: Relationship with catecholamines in women of reproductive age. J Psychiatr Res1998;32:5564.
  • 56
    Piletz JE, Halaris A. Involvement of I1-imidazoline receptors in mood disorders. Ann N Y Acad Sci1995;763:510519.
  • 57
    Molderings GJ, Gothert M, Christen O, Schafer SG. Imidazole receptors and blood pressure regulation. High receptor selectivity of moxonidine. Dtsch Med Wochenschr1993;118:953958.
  • 58
    Steffen G, Dendorfer A, Dominiak P. Imidazoline binding sites on PC12 cells and bovine chromaffin cells. Ann N Y Acad Sci1995;763:157162.
  • 59
    Piletz JE, Sletten K. Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther1993;267:14931502.
  • 60
    Atlas D, Burstein Y. Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur J Biochem1984;144:287293.
  • 61
    Atlas D, Burstein Y. Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS Lett1984;170:387390.
  • 62
    Reis DJ, Regunathan S. Agmatine: An endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst1998;72:8085.
  • 63
    Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brainTrends Pharmacol Sci2000;21:187193.
  • 64
    Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: An endogenous clonidine-displacing substance in the brain. Science1994;263:966969.
  • 65
    Piletz JE, Chikkala DN, Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther1995;272:581587.
  • 66
    Pinthong D, Hussain JF, Kendall DA, Wilson VG. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2-adrenoceptor binding sites. Br J Pharmacol1995;115:689695.
  • 67
    Pinthong D, Wright IK, Hanmer C, Millns P, Mason R, Kendall DA, Wilson VG. Agmatine recognizes alpha 2-adrenoceptor binding sites but neither activates nor inhibits alpha 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol1995;351:1016.
  • 68
    Musgrave IF, Badoer, E. Harmane produces hypotension following microinjection into the RVLM: Possible role of I-imidazoline receptors. Br J Pharmacol2000;129:10571059.
  • 69
    Moncrieff J. Determination of pharmacological levels of harmane, harmine and harmaline in mammalian brain tissue, cerebrospinal fluid and plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr1989;496:269278.
  • 70
    Anderson NJ, Tyacke RJ, Husbands SM, Nutt DJ, Hudson AL, Robinson ES. In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology2006;50:269276.
  • 71
    Anderson NJ, Seif I, Nutt DJ, Hudson AL, Robinson ES. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J Neurochem2006;96:15511559.
  • 72
    Prell GD, Martinelli GP, Holstein GR, et al. Imidazoleacetic acid-ribotide: An endogenous ligand that stimulates imidazol(in)e receptors. Proc Natl Acad Sci U S A2004;101:1367713682.
  • 73
    Parini A, Moudanos CG, Pizzinat N, Lanier SM. The elusive family of imidazoline binding sites. Trends Pharmacol Sci1996;17:1316.
  • 74
    Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP. ‘Seeing through a glass darkly’: Casting light on imidazoline ‘I’ sites. Trends Pharmacol Sci1998;19:381390.
  • 75
    Raddatz R, Savic SL, Bakthavachalam V, et al. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J Pharmacol Exp Ther2000;292:11351145.
  • 76
    Tyacke RJ, Robinson ES, Nutt DJ, Hudson AL. 5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: In vitro and in vivo characterisation in rat brain. Neuropharmacology2002;43:7583.
  • 77
    Diaz A, Mayet S, Dickenson AH. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. Eur J Pharmacol1997;333:915.
  • 78
    Rustenbeck I, Herrmann C, Ratzka P, Hasselblatt A. Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells. Naunyn Schmiedebergs Arch Pharmacol1997;356:410417.
  • 79
    Proks P, Ashcroft FM. Phentolamine block of KATP channels is mediated by Kir6.2. Proc Natl Acad Sci U S A1997;94:1171611720.
  • 80
    Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. Imidazolines and pancreatic hormone secretion. Ann N Y Acad Sci1999;881:217228.
  • 81
    Chan SL, Brown CA, Scarpello KE, Morgan NG. The imidazoline site involved in control of insulin secretion: Characteristics that distinguish it from I1- and I2-sites. Br J Pharmacol1994;112:10651070.
  • 82
    Clews J,   MN, Ramsden CA. Preparation of the I3 imidazoline receptor antagonist KU14R and related 2,3-dihyrobenzo[b]furan derivatives. Synthesis2001;10:15461550.
  • 83
    Squires PE, Hills CE, Rogers GJ, Garland P, Farley SR, Morgan NG. The putative imidazoline receptor agonist, harmane, promotes intracellular calcium mobilisation in pancreatic beta-cells. Eur J Pharmacol2004;501:3139.
  • 84
    Morgan NG, Cooper EJ, Squires PE, Hills CE, Parker CA, Hudson AL. Comparative effects of efaroxan and beta-carbolines on the secretory activity of rodent and human beta cells. Ann N Y Acad Sci2003;1009:167174.
  • 85
    Ernsberger P, Graves ME, Graff LM, et al. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann N Y Acad Sci1995;763:2242.
  • 86
    Molderings GJ, Bonisch H, Hammermann R, Gothert M, Bruss M. Noradrenaline release-inhibiting receptors on PC12 cells devoid of alpha(2(-)) and CB(1) receptors: Similarities to presynaptic imidazoline and edg receptors. Neurochem Int2002;40:157167.
  • 87
    Guroff G. PC12 cells as a model of neuronal differentiation. In: Bottenstein JE, Sato G, editors. Cell culture in the neurosciences: ed1. New York , Plenum Press, 1985;245272.
  • 88
    Regunathan S, Meeley MP, Reis DJ. Effect of clonidine on second messenger systems in rat adrenal gland. Life Sci1990;47:21272133.
  • 89
    Regunathan S, Evinger MJ, Meeley MP, Reis DJ. Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells. Biochem Pharmacol1991;42:20112018.
  • 90
    Liedtke CM, Furin J, Ernsberger P. Alpha 2-adrenergic, but not imidazole, agonists activate NaCl cotransport in rabbit tracheal epithelial cells. Am J Physiol1993;264(3 Pt 1):C568C576.
  • 91
    Greney H, Ronde P, Magnier C, et al. Coupling of I(1) imidazoline receptors to the cAMP pathway: Studies with a highly selective ligand, benazoline. Mol Pharmacol2000;57:11421151.
  • 92
    Liedtke CM, Ernsberger P. Regulation of electrolyte transport in rabbit tracheal epithelial cells by the I1-imidazoline agonist moxonidine. Ann N Y Acad Sci1995;763:401404.
  • 93
    Separovic D, Kester M, Ernsberger P. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol1996;49:668675.
  • 94
    Ernsberger P. Arachidonic acid release from PC12 pheochromocytoma cells is regulated by I1-imidazoline receptors. J Auton Nerv Syst1998;72:147154.
  • 95
    Muller-Decker K. Interruption of TPA-induced signals by an antiviral and antitumoral xanthate compound: Inhibition of a phospholipase C-type reaction. Biochem Biophys Res Commun1989;162:198205.
  • 96
    Separovic D, Kester M, Haxhiu MA, Ernsberger P. Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res1997;749:335339.
  • 97
    Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, Ernsberger P. The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem2001;79:931940.
  • 98
    Piletz JE, Ivanov TR, Sharp JD, et al. Imidazoline receptor antisera-selected (IRAS) cDNA: Cloning and characterization. DNA Cell Biol2000;19:319329.
  • 99
    Alahari SK, Lee JW, Juliano RL. Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol2000;151:114154.
  • 100
    Alahari SK, Reddig PJ, Juliano RL. The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK. EMBO J2004;23:27772788.
  • 101
    Dontenwill M, Piletz JE, Chen M, et al. IRAS is an anti-apoptotic protein. Ann N Y Acad Sci2003;1009:400412.
  • 102
    Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE. Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem2002;277:1943919447.
  • 103
    Gavras I, Manolis AJ, Gavras H. The alpha2 -adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens2001;19:21152124.
  • 104
    Esler M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: The transition from mechanisms to medical management. J Appl Physiol2010;108:227237.
  • 105
    Mobini R, Fu M, Jansson PA, Bergh CH, Scharin Tang M, Waagstein F, Andersson B. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: Acute effects of the imidazoline I1-receptor agonist moxonidine. Clin Sci (Lond)2006;110:32936.
  • 106
    Esler M, Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst1998;72:210219.
  • 107
    Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation2002;105:17971803.
  • 108
    Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittes J. The data monitoring experience in the MOXCON trial. Eur Heart J2004;25:1974198.
  • 109
    Ernsberger P, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, Friedman JE. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther1999;288:139147.
  • 110
    Sun Z, Ernsberger P. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine. J Pharmacol Exp Ther2007;320:845852.
  • 111
    Velliquette RA, Ernsberger P. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther2003;306:646657.
  • 112
    Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol2006;372:300312.
  • 113
    Edwards L, Ernsberger P. Cross-Talk between I1-imidazoline and insulin receptor signaling: A mechanism for moxonidine's antidiabetic actionsJ. Hypertension2000;18:S129.
  • 114
    Penicaud L, Berthault MF, Morin J, Dubar M, Ktorza A, Ferre P. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens Suppl1998;16:S45S49.
  • 115
    Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin2005;21:113119.
  • 116
    Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, Steinberg MI. Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes1999;48:10931100.
  • 117
    Lumb PJ, McMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract2004;58:465468.
  • 118
    Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: A comparison with metformin. Diabetes Obes Metab2006;8:456465.
  • 119
    Vengerovskii AI, Idrisova EM, Bushkova EA, Mananko EI, Krasnova NMThe influence of antihypertensive agents on plasmatic and vascular-thrombocytic homeostasis in metabolic syndrome. Eksp Klin Farmakol2008;71:812.
  • 120
    Topal E, Cikim AS, Cikim K, Temel I, Ozdemir R. The effect of moxonidine on endothelial dysfunction in metabolic syndrome. Am J Cardiovasc Drugs2006;6:343348.
  • 121
    Poyhonen-Alho MK, Manhem K, Katzman P, et al. Central sympatholytic therapy has antiinflammatory properties in hypertensive postmenopausal women. J Hypertens2008;26:24452449.
  • 122
    Ebinc H, Ozkurt ZN, Ebinc FA, Ucardag D, Caglayan O, Yilmaz M. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res2008;36:8087.